Correction to: Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients ’ Real-World Insights for Optimizing Outcomes
(Source: Advances in Therapy)
Source: Advances in Therapy - March 24, 2024 Category: Drugs & Pharmacology Source Type: research

‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar
ConclusionOverall, the Totality of Evidence provided for biosimilar adalimumab, SDZ-ADL, confirmed the analytical, functional and clinical similarity of SDZ-ADL to REF-ADL, supporting its regulatory approval and providing a data bridge with which to evaluate and support the approval of citrate-free HCF SDZ-ADL for clinical use. (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research

Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300  Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
ConclusionsThis study showed that initiation of insulin therapy with Gla-300 in people with T2DM using an individualized approach is more effective in achieving an HbA1c target. Moreover, earlier initiation of insulin therapy in people with suboptimally controlled T2DM may increase the success rate of glycemic control.A graphical abstract is available with this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review
ConclusionsAlthough targeted therapies demonstrate systemic benefits for patients with NSCLC, BrMs, and AGAs, there remains a continued need for effective therapies to treat and prevent BrMs in this population. Increased BBB permeability of emerging therapies may improve outcomes for this population. (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research

Enhancing Drug Management, Cost Savings, and Staff Satisfaction in Anesthesiology: A Quality Improvement Project in a Chinese Tertiary Hospital
ConclusionThe quality improvement project has yielded remarkable positive outcomes, serving as a model worthy of reference and replication in similar healthcare settings. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
ConclusionThis anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase  Inhibitor
ConclusionsFindings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results. (Source: Advances in Therapy)
Source: Advances in Therapy - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Perioperative and Long-Term Outcomes in Patients Undergoing Synchronous Carotid Endarterectomy and Coronary Artery Bypass Grafting: A Single-Center Experience
ConclusionPatients undergoing synchronous CEA and CABG face an elevated risk of perioperative cardiovascular events, particularly an increased stroke risk in patients with symptomatic and bilateral ICA stenosis.Graphical Abstract available for this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Adverse Drug Events Observed with the Newly Approved Remimazolam in Comparison to Propofol for General Anesthesia in Patients Undergoing Surgery: A Meta-analysis
ConclusionOur current analysis showed that the newly approved remimazolam was apparently associated with significantly fewer adverse drug events in comparison to propofol for GA in patients undergoing surgery. Therefore, this new drug should be further studied and more research with larger population sizes should be carried out to confirm this hypothesis. (Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
(Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis
(Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Correction to: PRESTO 2: An International Survey to Evaluate Patients ’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
(Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Comparison of Healthcare Costs for Women with Treated Versus Untreated Vasomotor Symptoms Due to Menopause
ConclusionsMost women with VMS due to menopause were not treated within 6  months following diagnosis. While both on- and off-label treatment increased the total cost of care compared with untreated controls, those increases were modest in magnitude and should not impede treatment for women who report symptom improvement as a result of treatment. (Source: Advances in Therapy)
Source: Advances in Therapy - March 11, 2024 Category: Drugs & Pharmacology Source Type: research

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review
AbstractAdalimumab (ADL, Humira®, reference product), an anti-TNF- α biologic, has transformed the treatment of chronic, immune-mediated inflammatory diseases. However, the high cost of ADL therapy has driven the development of more affordable ADL biosimilars, agents with no clinically meaningful differences from the reference product. This review summarizes the p roduct attributes of reference ADL and the nine ADL biosimilars approved and available in the USA in relation to patient experience of injection-site pain (ISP). Product formulation, delivery volume and device features (e.g., type and needle gauge size) influen...
Source: Advances in Therapy - March 11, 2024 Category: Drugs & Pharmacology Source Type: research

The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis
ConclusionThese results quantify the significant and diverse burdens associated with MDD and prior MDD medication treatment failure. (Source: Advances in Therapy)
Source: Advances in Therapy - March 11, 2024 Category: Drugs & Pharmacology Source Type: research